Fundz
Real-time · AI · Cross-signal

Tessera Therapeutics just moved. Here's exactly what to do next.

Who to reach, what to say, and why now — on Tessera Therapeutics, plus every contract, funding round, and exec hire that follows. Verified, ICP-ranked contacts on demand (email + mobile).

Used by professionals at BlackRock, Oracle, Kleiner Perkins, HubSpot, and other leading firms — built on 10 years of proprietary signal data.

Choose your planRequest a demo
▶
Watch the 2-minute tour · with sound

Tessera Therapeutics Enters Agreement with Bill & Melinda Gates Foundation to Fund Sickle Cell Disease Program

Dec 18, 2024•over 1 year ago

Contract Type

agreement

Somerville

Description

Tessera Therapeutics has entered into an agreement with the Bill & Melinda Gates Foundation to jointly fund the company’s in vivo program for sickle cell disease (SCD). The funding includes an initial investment, with potential total investment of up to $50 million, from the Gates Foundation intended to support the development of Tessera's SCD program into the clinic.

Company Information

Company

Tessera Therapeutics

Location

Somerville, Pennsylvania, United States

About

Tessera Therapeutics is pioneering GENE WRITING technology, which consists of multiple technology platforms designed to offer scientists and clinicians the ability to write therapeutic messages into the human genome, thereby curing diseases at their source. The GENE WRITING platform allows the correction of single nucleotides, the deletion or insertion of short sequences of DNA, and the writing of entire genes into the genome, offering the potential for a new category of genetic medicines with broad applications both in vivo and ex vivo. Tessera Therapeutics was founded by Flagship Pioneering in 2018, a life sciences innovation enterprise that conceives, resources, and develops first-in-category companies to transform human health and sustainability. For more information about Tessera, please visit www.tesseratherapeutics.com.

Predictive Intelligence
Strategic

ML-powered predictions for Tessera Therapeutics's next move

Learn about Strategic plan

Agreement Insights

Based on industry data
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months